Drug Trial Radar · NCT00172133
Open Label Extension Study of PREOS
Last checked: Nov 20, 2026Latest source record: May 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,683
Actual
Start
Oct 16, 2001
Primary completion
Apr 13, 2005
Study completion Apr 13, 2005
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an Open Label Extension Study (OLES) for patients who participated in the 18 month double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study) studying the effect of ALX1-11, recombinant human parathyroid hormone, rhPTH(1-84), on vertebral fracture incidence. The primary objective of this study is to evaluate the safety of continued dosing with ALX1-11, up to a maximum of 24 months, in postmenopausal osteoporotic women who participated in Protocol ALX1 11 93001.
Conditions
- Osteoporosis
Interventions
ALX1-11 (drug)Drug
100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety of continued dosing with ALX1-11, up to a maximum of 24 months, in postmenopausal osteoporotic women who participated in Protocol ALX1-11-93001 (TOP).Time frame: 24 months of treatment
Locations
132 sites in 8 countries. Site status is shown where the registry gives one.
'The University of Alabama at Birmingham
Birmingham, Alabama
'Rheumatology Associates of North Alabama
Huntsville, Alabama
'Radiant Research - Phoenix North
Phoenix, Arizona
'Osteoporosis Medical Center
Beverly Hills, California
'East Bay Clinical Trial Center
Concord, California
'Loma Linda Osteoporosis Research Center
Loma Linda, California
Foundation for Osteoporosis Research
Oakland, California
'Desert Medical Advances
Palm Desert, California
'VA Palo Alto Health Care System
Palo Alto, California
'Boling Clinical Trials
Rancho Cucamonga, California
'S.D. Arthritis & Osteoporosis Medical Clinic
San Diego, California
'Radiant Research - San Diego
San Diego, California
'San Francisco General Hospital
San Francisco, California
'Longmont Medical Research Network
Longmont, Colorado
'Northeast Clinical Research, LLC
Hamden, Connecticut
'RASF - Clinical Research Center
Boca Raton, Florida
'The Center for Diabetes and Endocrine Care
Hollywood, Florida
'Florida Wellcare Alliance
Inverness, Florida
'Renstar Medical Group
Ocala, Florida
'The Arthritis Center
Palm Harbor, Florida
'The Centre for Arthritis and Rheumatic Diseases
South Miami, Florida
'Radiant Research - Stuart & LakeWorth
Stuart, Florida
'Palm Beach Research Center
West Palm Beach, Florida
'Radiant Research
Honolulu, Hawaii
'Intermountain Orthopaedics
Boise, Idaho
Rush-Prebyterian-St.Luke's Medical Center
Chicago, Illinois
'The University of Chicago
Chicago, Illinois
'University Hospital & Outpatient Center
Indianapolis, Indiana
'Mercy Arthritis and Osteoporosis Center
Des Moines, Iowa
'Wichita Clinic
Wichita, Kansas
'Ochsner Clinic
New Orleans, Louisiana
'Maine Center for Osteoporosis Research & Education
Bangor, Maine
'Bethesda Health Research Center
Bethesda, Maryland
'The Osteoporosis and Clinical Trials Center
Cumberland, Maryland
'Arthritis & Osteoporosis Center of Maryland
Frederick, Maryland
'The Center for Rheumatology and Bone Research
Wheaton, Maryland
'Brigham & Women's Hospital
Boston, Massachusetts
'Michigan Bone & Mineral Clinic
Detroit, Michigan
'Desoto Family Medical Center
Olive Branch, Mississippi
'St. John's Medical Research Group
Springfield, Missouri
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.